Vera Therapeutics, Inc.
VERA
$28.82
-$0.48-1.64%
| Weiss Ratings | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.82 | |||
| Price History | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.78% | |||
| 30-Day Total Return | -15.46% | |||
| 60-Day Total Return | -40.53% | |||
| 90-Day Total Return | -27.57% | |||
| Year to Date Total Return | -31.71% | |||
| 1-Year Total Return | -33.44% | |||
| 2-Year Total Return | 248.07% | |||
| 3-Year Total Return | 34.74% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -43.23% | |||
| 52-Week Low % Change | 12.74% | |||
| Price | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $51.61 | |||
| 52-Week Low Price | $25.99 | |||
| 52-Week Low Price (Date) | Feb 14, 2025 | |||
| 52-Week High Price (Date) | Nov 13, 2024 | |||
| Valuation | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.87B | |||
| Enterprise Value | 1.28B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.74 | |||
| Earnings Per Share Growth | 19.86% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.23 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $28.82 | |||
| Enterprise Value/EBITDA (TTM) | -9.53 | |||
| Enterprise Value/EBIT | -7.67 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 60.69M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 770 0077 | |||
| Address | 8000 Marina Boulevard Brisbane, CA 94005 | |||
| Website | veratx.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.14% | |||
| Return on Equity | -- | |||
| Income Statement | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -134.48M | |||
| EBIT (TTM) | -167.17M | |||
| Net Income (TTM) | -152.15M | |||
| Net Income Avl. to Common (TTM) | -152.15M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -69.27% | |||
| EPS Diluted (TTM) | -2.74 | |||
| EPS Diluted Growth (Q YOY) | -23.98% | |||
| Balance Sheet | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 640.85M | |||
| Cash Per Share (Q) | $10.56 | |||
| Total Current Assets (Q) | 651.22M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 577.16M | |||
| Current Ratio (Q) | 25.668 | |||
| Book Value Per Share (Q) | $9.08 | |||
| Total Assets (Q) | 655.68M | |||
| Total Current Liabilities (Q) | 25.37M | |||
| Total Debt (Q) | 54.64M | |||
| Total Liabilities (Q) | 78.53M | |||
| Total Common Equity (Q) | 577.16M | |||
| Cash Flow | VERA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -425.03M | |||
| Cash from Financing (TTM) | 606.67M | |||
| Net Change in Cash (TTM) | 46.97M | |||
| Levered Free Cash Flow (TTM) | -84.35M | |||
| Cash from Operations (TTM) | -134.68M | |||
